Conor Gallagher, PhD, is now the Chief Scientific Officer at Revance Therapeutics.
Mr. Gallagher joined Revance in April 2018 to lead the Medical Affairs group. Over the past few years, he expanded his role to oversee R&D, process development and analytical development under the umbrella of Scientific Innovation. Additionally, he leads Revance’s team working on the biosimilar program. Prior to joining Revance, Mr. Gallagher spent 12 years at Allergan in medical affairs roles. He received his PhD in Neuroscience from the University of Toronto, an MSc in Anatomy from University College, and his undergraduate degree in Physiotherapy from University College Dublin, Ireland.
